Aquestive Therapeutics (NASDAQ:AQST) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report released on Tuesday, MarketBeat reports. The brokerage issued an overweight rating and a $17.00 price target on the stock. Cantor Fitzgerald also issued estimates for Aquestive Therapeutics’ FY2024 earnings at ($0.45) EPS.

Several other analysts also recently commented on the stock. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Finally, Leerink Partners lifted their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Trading Up 5.2 %

NASDAQ:AQST opened at $3.64 on Tuesday. The firm has a fifty day simple moving average of $4.74 and a two-hundred day simple moving average of $4.06. The stock has a market capitalization of $331.89 million, a price-to-earnings ratio of -8.09 and a beta of 2.62. Aquestive Therapeutics has a 12 month low of $1.84 and a 12 month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. Equities analysts predict that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp raised its position in Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after purchasing an additional 512,682 shares in the last quarter. Blue Owl Capital Holdings LP increased its position in shares of Aquestive Therapeutics by 30.3% in the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after acquiring an additional 265,000 shares during the period. Bank of New York Mellon Corp bought a new position in Aquestive Therapeutics during the 2nd quarter valued at approximately $594,000. Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics during the third quarter valued at approximately $995,000. Finally, Wellington Management Group LLP bought a new position in Aquestive Therapeutics in the 3rd quarter worth $922,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.